Recent News

• 11.19.2025 - SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
• 11.17.2025 - Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
• 11.17.2025 - Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
• 11.05.2025 - SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
• 11.05.2025 - SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
• 10.15.2025 - SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study
• 09.30.2025 - SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)
• 09.04.2025 - SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)
• 08.25.2025 - SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025
• 08.13.2025 - SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Recent Filings

• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.05.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.15.2025 - 8-K Current report
• 10.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.01.2025 - 8-K Current report
• 06.30.2025 - 4 Statement of changes in beneficial ownership of securities